In recent trading session, Recursion Pharmaceuticals Inc (NASDAQ:RXRX) saw 9.46 million shares changing hands at last check today with its beta currently measuring 0.87. Company’s recent per share price level of $10.02 trading at -$0.33 or -3.19% at last check today assigns it a market valuation of $3.92B. That most recent trading price of RXRX’s stock is at a discount of -57.09% from its 52-week high price of $15.74 and is indicating a premium of 44.11% from its 52-week low price of $5.60.
For Recursion Pharmaceuticals Inc (RXRX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.43. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.42 in the current quarter.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information
Upright in the red during last session for losing -3.19%, in the last five days RXRX remained trading in the green while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $10.02 price level, adding 18.93% to its value on the day. Recursion Pharmaceuticals Inc’s shares saw a change of 48.22% in year-to-date performance and have moved 17.88% in past 5-day. Recursion Pharmaceuticals Inc (NASDAQ:RXRX) showed a performance of 33.78% in past 30-days.
Wall Street analysts have assigned a consensus price target of 11 to the stock, which implies a rise of 8.91% to its recent value today. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 12. It follows that stock’s current price would jump 40.12% in reaching the projected high whereas dropping to the targeted low would mean a gain of 40.12% for stock’s current value.
Recursion Pharmaceuticals Inc (RXRX) estimates and forecasts
This year revenue growth is estimated to rise 52.11% from the last financial year’s standing.
7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 19.04M for the same. And 3 analysts are in estimates of company making revenue of 12M in the next quarter. Company posted 10.89M and 13.79M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -43.41% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 2.61% while estimates for its earnings growth in next 5 years are of 4.49%.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX)’s Major holders
ARK INVESTMENT MANAGEMENT LLC is the top institutional holder at RXRX for having 28.14 million shares of worth $211.07 million. And as of 2024-06-30, it was holding 11.6199 of the company’s outstanding shares.
The second largest institutional holder is BAILLIE GIFFORD & CO, which was holding about 26.59 million shares on 2024-06-30. The number of shares represents firm’s hold over 11.266 of outstanding shares, having a total worth of $199.42 million.
On the other hand, ARK ETF Tr-ARK Innovation ETF and ARK ETF Tr-ARK Genomic Revolution ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024, the former fund manager was holding 18.28 shares of worth $181.5 million or 4.76% of the total outstanding shares. The later fund manager was in possession of 11.51 shares on Dec 31, 2024, making its stake of worth around $114.27 million in the company or a holder of 3.00% of company’s stock.
